We at AKSIA Healthcare are proud to announce the new strategic partnership with NuVision Biotherapies. NuVision Biotherapies based in Nottingham’s MediCity campus is a company focused on tissue therapy, specializing in the development and provision of various products and processes for advancements in ophthalmology. This partnership allowed NuVision Biotherapies to offer its amniotic membrane products (Omnigen and OmniLenz®️) to ophthalmology specialists in the Middle East, meeting clinical needs and supporting Vision 2030 in Saudi Arabia. Omnigen and OmniLenz®️, have seen success in Kuwait public hospitals. Omnigen, a stable amniotic membrane-derived material, aids natural healing in ophthalmic conditions, complemented by OmniLenz®️, a suture-free transplantation bandage contact lens. Andy Hill, CEO of NuVision Biotherapies said that this expansion presents an exciting opportunity to deliver solutions into a wider Middle Eastern market and work with healthcare professionals in new territories. He also said that they’re looking forward to building on to the successful partnership with AKSIA Healthcare and meeting the clinical need for their products in territories across the Middle East. Ahmed Sallam, Managing Director at AKSIA Healthcare, emphasizes their commitment to advancing ophthalmology solutions in the region. “This expansion aligns with our dedication to supporting Vision 2030 and contributing to the healthcare evolution of Saudi Arabia,” he stated. With this partnership, NuVision Biotherapies and AKSIA Healthcare aim to significantly improve access to quality eye care in the Middle East.